Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05572684 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by NextCure.
- Active
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
- 17
- Study locations
NCT05572684: Active Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by NextCure.
NCT05572684 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is active but no longer recruiting, run by NextCure. The registered enrollment target is 97 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05572684, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by NextCure.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
Primary Outcome
Number of Participants With Treatment-emergent Adverse Events
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG NC410
Study Locations (17)
Texas
- UT Southwestern Medical Center - Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
- UT Health San Antonio - San Antonio
- Texas Oncology - San Antonio - San Antonio
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- NYU Langone Health - New York
Virginia
- Inova Schar Cancer Institute - Fairfax
- Virginia Cancer Specialist - Fairfax
Arizona
- Arizona Oncology Associates - Tucson
Colorado
- Rocky Mountain Cancer Centers - Aurora
Kentucky
- St. Elizabeth Edgewood Hospital - Edgewood
Louisiana
- Ochsner Cancer Institute - New Orleans
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
What the registry record for NCT05572684 still lists
NCT05572684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower).
The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT05572684 lists 17 locations in 11 states (Texas, New York, Virginia).
Frequently Asked Questions
What is clinical trial NCT05572684 about?
NCT05572684 is a clinical study titled "A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors". This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refr...
What is the current status of trial NCT05572684?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2022-10-06. Estimated completion is 2025-11.
What conditions does trial NCT05572684 study?
This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT05572684?
The interventions under investigation include: pembrolizumab (DRUG), NC410 (DRUG).
Who is sponsoring clinical trial NCT05572684?
This trial is sponsored by NextCure, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05572684 being conducted?
This trial has 17 study locations across Arizona, Colorado, Kentucky, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05572684's enrollment target sits among peer trials
97 222nd of 381 higher than 159 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI